The Fort Worth Press - The scientist rewriting DNA, and the future of medicine

USD -
AED 3.672991
AFN 66.000087
ALL 82.399047
AMD 381.504003
ANG 1.790403
AOA 917.000073
ARS 1451.743901
AUD 1.50218
AWG 1.8025
AZN 1.69912
BAM 1.666503
BBD 2.013642
BDT 122.171618
BGN 1.66372
BHD 0.377029
BIF 2960
BMD 1
BND 1.290015
BOB 6.92273
BRL 5.592102
BSD 0.999749
BTN 89.631315
BWP 13.185989
BYN 2.907816
BYR 19600
BZD 2.010685
CAD 1.37495
CDF 2260.000397
CHF 0.79203
CLF 0.023195
CLP 909.939844
CNY 7.04095
CNH 7.03154
COP 3800
CRC 498.36831
CUC 1
CUP 26.5
CVE 94.449702
CZK 20.702498
DJF 177.719835
DKK 6.35227
DOP 62.601015
DZD 129.731026
EGP 47.436323
ERN 15
ETB 155.349699
EUR 0.85057
FJD 2.28735
FKP 0.750114
GBP 0.743075
GEL 2.684968
GGP 0.750114
GHS 11.48031
GIP 0.750114
GMD 73.504195
GNF 8685.999814
GTQ 7.660619
GYD 209.163024
HKD 7.780349
HNL 26.349859
HRK 6.408804
HTG 130.901562
HUF 330.495499
IDR 16760.35
ILS 3.200197
IMP 0.750114
INR 89.621596
IQD 1310
IRR 42100.000171
ISK 125.879875
JEP 0.750114
JMD 159.578049
JOD 0.708945
JPY 157.012028
KES 128.897158
KGS 87.450013
KHR 4010.999827
KMF 418.999983
KPW 899.999969
KRW 1481.21994
KWD 0.307402
KYD 0.833142
KZT 515.528744
LAK 21634.999932
LBP 89599.999836
LKR 309.526853
LRD 177.497801
LSL 16.729883
LTL 2.95274
LVL 0.60489
LYD 5.425025
MAD 9.13875
MDL 16.926118
MGA 4547.496354
MKD 52.364728
MMK 2100.312258
MNT 3551.223311
MOP 8.011554
MRU 39.759791
MUR 46.149909
MVR 15.46001
MWK 1737.000161
MXN 17.973855
MYR 4.077799
MZN 63.890431
NAD 16.729751
NGN 1459.839882
NIO 36.703721
NOK 10.109295
NPR 143.404875
NZD 1.72567
OMR 0.384499
PAB 0.99977
PEN 3.366503
PGK 4.25025
PHP 58.800496
PKR 280.150253
PLN 3.58629
PYG 6755.311671
QAR 3.641101
RON 4.328398
RSD 99.855021
RUB 78.801385
RWF 1452
SAR 3.750276
SBD 8.146749
SCR 14.189339
SDG 601.505751
SEK 9.235035
SGD 1.28834
SHP 0.750259
SLE 24.049922
SLL 20969.503664
SOS 571.488724
SRD 38.406503
STD 20697.981008
STN 21.25
SVC 8.748333
SYP 11058.38145
SZL 16.705021
THB 31.143981
TJS 9.197788
TMT 3.5
TND 2.895015
TOP 2.40776
TRY 42.814301
TTD 6.796861
TWD 31.49105
TZS 2485.981003
UAH 42.082661
UGX 3602.605669
UYU 39.187284
UZS 12002.498951
VES 282.15965
VND 26340
VUV 120.603378
WST 2.787816
XAF 558.912945
XAG 0.014508
XAU 0.000225
XCD 2.70255
XCG 1.801846
XDR 0.695829
XOF 558.495114
XPF 101.875012
YER 238.492219
ZAR 16.7172
ZMK 9001.197229
ZMW 22.594085
ZWL 321.999592
  • RBGPF

    0.7800

    81

    +0.96%

  • SCS

    0.0200

    16.14

    +0.12%

  • RYCEF

    -0.1100

    15.5

    -0.71%

  • CMSC

    -0.0500

    23.12

    -0.22%

  • BCC

    -0.5400

    74.23

    -0.73%

  • NGG

    0.3000

    76.41

    +0.39%

  • RELX

    0.2500

    40.98

    +0.61%

  • CMSD

    -0.0500

    23.2

    -0.22%

  • VOD

    0.0400

    12.88

    +0.31%

  • RIO

    1.7800

    80.1

    +2.22%

  • JRI

    -0.0100

    13.37

    -0.07%

  • BCE

    -0.1100

    22.73

    -0.48%

  • GSK

    -0.0200

    48.59

    -0.04%

  • BTI

    0.3200

    56.77

    +0.56%

  • AZN

    0.1900

    91.55

    +0.21%

  • BP

    0.2000

    34.14

    +0.59%

The scientist rewriting DNA, and the future of medicine
The scientist rewriting DNA, and the future of medicine / Photo: © Broad Institute of Harvard and MIT,/AFP

The scientist rewriting DNA, and the future of medicine

A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.

Text size:

A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.

He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.

He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.

"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.

- Correcting the code -

DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.

Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.

It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.

"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.

That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.

Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.

These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.

In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.

While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.

"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.

- Cystic fibrosis hope -

Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.

About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.

To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.

If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.

Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."

Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.

Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.

"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."

This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).

"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."

C.M.Harper--TFWP